Development of antiproliferative phenylmaleimides that activate the unfolded protein response.
The current paper presents the synthesis and evaluation of a series of maleimides that were designed to inhibit the Cdc25 phosphatase by alkylation of catalytically essential cysteine residues. Although in HepB3 cell culture assays the analogues did exhibit antiproliferative IC(50) values ranging from sub-micromolar to greater than 100 microM, inhibition of Cdc25 through cysteine alkylation could not be demonstrated. It was also found that analysis using fluorescence activated cell sorting (FACS) following treatment with the most potent analogue (1t) did not provide data consistent with inhibition at one specific point in the cell cycle, as would be expected if Cdc25A were inhibited. Further studies with a subset of analogues resulted in a correlation of antiproliferative potencies with activation of the unfolded protein response (UPR). The UPR is a regulatory pathway that temporarily suspends protein production when misfolding of proteins occurs within the endoplastic reticulum (ER). In addition, ER chaperones that promote proper refolding become up-regulated. If cellular damage cannot be resolved by these mechanisms, then the UPR can initiate apoptosis. The current study indicates that these maleimide analogues lead to UPR activation, which is predictive of the selective antiproliferative activity of the series.
Muus
Ulrike
U
Chemical Biology Laboratory, Molecular Discovery Program, NCI-Frederick, Frederick, MD 21702, USA.
Hose
Curtis
C
Yao
Wei
W
Kosakowska-Cholody
Teresa
T
Farnsworth
David
D
Dyba
Marzena
M
Lountos
George T
GT
Waugh
David S
DS
Monks
Anne
A
Burke
Terrence R
TR
Michejda
Christopher J
CJ
D018906:Antineoplastic Agents, Alkylating / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D045744:Cell Line, Tumor; D004721:Endoplasmic Reticulum / Q000378:metabolism; D006801:Humans; D008301:Maleimides / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D056811:Unfolded Protein Response; D020687:cdc25 Phosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism
D018906:Antineoplastic Agents, Alkylating; D008301:Maleimides; D020687:cdc25 Phosphatases
Clin Chem. 2002 Oct;48(10):1819-27
12324512
J Org Chem. 1998 Apr 17;63(8):2646-2655
11672132
Cancer Res. 2009 Feb 15;69(4):1545-52
19190324
Biochem Pharmacol. 2006 Nov 15;72(10):1217-27
16930563
J Biol Chem. 1995 Nov 24;270(47):28304-10
7499329
J Biol Chem. 2003 Sep 26;278(39):37375-85
12871976
Cancer Biol Ther. 2007 May;6(5):705-11
17404501
Curr Opin Cell Biol. 2006 Apr;18(2):185-91
16488126
Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29
17565364
Semin Cell Dev Biol. 2007 Dec;18(6):716-31
18023214
Nat Rev Drug Discov. 2002 Dec;1(12):961-76
12461518
Cell Mol Life Sci. 2008 Mar;65(6):862-94
18038217
Mol Cancer Ther. 2006 Jun;5(6):1511-9
16818510
Bioorg Med Chem Lett. 1998 Sep 22;8(18):2507-10
9873570
Oncogene. 2003 Jun 19;22(25):3827-32
12813455
J Biol Chem. 2003 Sep 12;278(37):34864-73
12840028
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3604-9
16505371
Apoptosis. 2009 Aug;14(8):996-1007
19360473
Antioxid Redox Signal. 2007 Dec;9(12):2277-93
17979528
J Biol Chem. 2009 Mar 13;284(11):6661-73
19131336
Nature. 1999 Jan 21;397(6716):271-4
9930704
J Cell Biol. 2001 May 28;153(5):1011-22
11381086
J Cell Biochem. 2003 Dec 15;90(6):1242-9
14635196
EMBO J. 2005 Mar 23;24(6):1243-55
15775988
Neurology. 2006 Jan 24;66(2 Suppl 1):S102-9
16432136
EMBO Rep. 2006 Sep;7(9):880-5
16953201